Snowden Capital Advisors’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
VCM
VPM
Snowden Capital Advisors's MRNA Position: Q1 2026 in Review
Snowden Capital Advisors increased its Moderna (MRNA) stake by 1.2% in Q1 2026, buying an estimated $7.23K and bringing the position to 12,722 shares worth $646K. The position accounts for 0.02% of the portfolio, ranked #686.
Snowden Capital Advisors first reported a position in MRNA in Q3 2020 and has held it in 18 quarters since. The position peaked at $3.11M in Q2 2025. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.
- Snowden Capital Advisors held 12,722 shares of Moderna worth $646K as of Q1 2026.
- Snowden Capital Advisors bought 155 Moderna shares in Q1 2026, an estimated $7.23K.
- Moderna made up 0.02% of Snowden Capital Advisors's portfolio in Q1 2026, its #686 holding.
- Snowden Capital Advisors first reported a position in Moderna in Q3 2020 and has held it in 18 quarters since.
- Snowden Capital Advisors's Moderna position peaked at $3.11M in Q2 2025.
- 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.
Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.